Intelligence Feed event · Equity · 2026-09-09

    Dentsply Sirona reports Q2 adjusted EPS of $0.52 and maintains $3.5B-$3.6B sales outlook

    Question

    Dentsply Sirona reports Q2 adjusted EPS of $0.52 and maintains $3.5B-$3.6B sales outlook

    Direct answer

    Dentsply Sirona outperformed quarterly bottom-line expectations with adjusted EPS of $0.52 versus $0.36 expected, supported by cost discipline and specialized healthcare product momentum. Despite annual revenue falling 4.1% due to softer dental equipment demand, the company reaffirmed full-year sales targets of $3.5-$3.6 billion and adjusted EPS of $1.40-$1.50.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-09
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Dentsply Sirona reports Q2 adjusted EPS of $0.52 and maintains $3.5B-$3.6B sales outlook”, revision 1, evidence through 2026-09-09. https://marketontology.com/market-events/2026-09-09/dentsply-sirona-reports-q2-adjusted-eps-of-0-52-and-maintains-3-5b-3-6b-sales-ou-fa519b

    EQUITY
    Dentsply Sirona reports Q2 adjusted EPS of $0.52 and maintains $3.5B-$3.6B sales outlook
    Dentsply Sirona outperformed quarterly bottom-line expectations with adjusted EPS of $0.52 versus $0.36 expected, supported by cost discipline and specialized healthcare product momentum. Despite annual revenue falling 4.1% due to softer dental equipment demand, the company reaffirmed full-year sales targets of $3.5-$3.6 billion and adjusted EPS of $1.40-$1.50.
    XRAYALGN
    Impact
    60
    SEP 9
    SIG
    82%
    XRAYALGN
    Dentsply Sirona reports Q2 adjusted EPS of $0.52 and maintains $3.5B-$3.6B sales outlook
    Dentsply Sirona outperformed quarterly bottom-line expectations with adjusted EPS of $0.52 versus $0.36 expected, supported by cost discipline and specialized healthcare product momentum. Despite annual revenue falling 4.1% due to softer dental equipment demand, the company reaffirmed full-year sales targets of $3.5-$3.6 billion and adjusted EPS of $1.40-$1.50.
    → Cost containment and 7.1% Wellspect growth offset broader 4.1% dental equipment volume declines to protect full-year $1.40-$1.50 EPS guidance.
    Impact
    Dentsply Sirona outperformed quarterly bottom-line expectations with adjusted EPS of $0.52 versus $0.36 expected, supported by cost discipline and specialized healthcare product momentum. Despite annual revenue falling 4.1% due to softer dental equipment demand, the company reaffirmed full-year sales targets of $3.5-$3.6 billion and adjusted EPS of $1.40-$1.50.
    Affected
    XRAYALGN
    Transmission
    Cost containment and 7.1% Wellspect growth offset broader 4.1% dental equipment volume declines to protect full-year $1.40-$1.50 EPS guidance.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    XRAYoperating cost containment cushioning top-line contractionMixed1-5dQ2 adjusted EPS beat at $0.52 vs $0.36 consensus despite 4.1% YoY revenue decline.
    ALGNdental supply and procedural volume read-acrossWatch1-4wAlign Technology shares market exposure to elective dental consumer spending trends.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    XRAYMixed10.72 2026-09-09-2.05%-5.41%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month